Interactions Between CYP3A5*3 and POR*28 Polymorphisms and Lipid Lowering Response with Atorvastatin

[1] Naci H(2013)Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials Eur J Prev Cardiol. 20 641-657

[2] Brugts JJ(2013)Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial Clin Ther. 35 1350-1360

[3] Fleurence R(2012)Clinical response to statins: mechanism(s) of variable activity and adverse effects Ann Med. 44 419-432

[4] Kim SH(2014)Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins Nat Commun. 28 5068-331

[5] Kim MK(2012)Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6 PLoS One. 7 e38495-883

[6] Seo HS(2014)Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients Mol Diagn Ther. 18 323-1291

[7] Sirtori CR(2009)The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test Pharmacogenet Genomics. 19 877-525

[8] Mombelli G(2011)The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients Pharmacogenomics. 12 1281-1671

[9] Triolo M(2004)Lipid-lowering response to statins is affected by CYP3A5 polymorphism Pharmacogenetics. 14 523-334

[10] Postmus I(2002)CYP3A5 variant allele frequencies in Dutch Caucasians Clin Chem. 48 1668-391

[1] Naci H(2013)Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials Eur J Prev Cardiol. 20 641-657

[2] Brugts JJ(2013)Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial Clin Ther. 35 1350-1360

[3] Fleurence R(2012)Clinical response to statins: mechanism(s) of variable activity and adverse effects Ann Med. 44 419-432

[4] Kim SH(2014)Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins Nat Commun. 28 5068-331

[5] Kim MK(2012)Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6 PLoS One. 7 e38495-883

[6] Seo HS(2014)Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients Mol Diagn Ther. 18 323-1291

[7] Sirtori CR(2009)The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test Pharmacogenet Genomics. 19 877-525

[8] Mombelli G(2011)The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients Pharmacogenomics. 12 1281-1671

[9] Triolo M(2004)Lipid-lowering response to statins is affected by CYP3A5 polymorphism Pharmacogenetics. 14 523-334

[10] Postmus I(2002)CYP3A5 variant allele frequencies in Dutch Caucasians Clin Chem. 48 1668-391